Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate... von Prawjaeng, Juthamas, Leelahavarong, Pattara, Budtarad, Nuttakarn, Pilasant, Songyot, Chanjam, Chonticha, Katchamart, Wanruchada, Narongroeknawin, Pongthorn, Kitumnuaypong, Tasanee

Volltext

Cost–utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand von Kittiratchakool, Nitichen, Kulpokin, Disorn, Chanjam, Chonticha, Vilaiyuk, Soamarat, Charuvanij, Sirirat, Phongsamart, Gun, Khaosut, Parichat, Tanya, Manasita, Nanagara, Ratanavadee, Nantapaisarn, Sira, Leelahavarong, Pattara

Volltext

Cost-utility analysis of biologic disease-modifying antirheumatic drugs combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity von Prawjaeng, Juthamas, Leelahavarong, Pattara, Budtarad, Nuttakarn, Pilasant, Songyot, Chanjam, Chonticha, Katchamart, Wanruchada, Narongroeknawin, Pongthorn, Kitumnuaypong, Tasanee

Volltext